ArticleRespiratory research2025
Activation of WDHD1 by DNA demethylases promotes MINPP1 transcription and glycolysis in lung adenocarcinoma progression.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMetabolic disturbance, particularly of glucose metabolism, is a hallmark of tumors, including non-small cell lung cancer. This study mainly analyzed the role of multiple inositol polyphosphate phosphatase 1 (MINPP1) in regulating glycolysis in lung adenocarcinoma (LUAD) in vitro and in vivo.
methodsFirst, the differential expression of ten-eleven translocation (TET)1/TET3, WD repeat and HMG-box DNA-binding protein 1 (WDHD1), and MINPP1 in tumors and paracancerous tissues of LUAD patients was measured using RT-qPCR and western blot assays. The effects of the WDHD1/MINPP1 axis on the proliferation and glycolysis of LUAD were explored by lentivirus-mediated gene intervention techniques or treatment with the glycolysis inhibitor 2-deoxyglucose (2-DG). The transcriptional regulation of WDHD1 and MINPP1 was probed using ChIP-qPCR, dual-luciferase assay, RT-qPCR, and western blot analyses. The association of TET1/TET3 with WDHD1 promoter demethylation was assessed using qMSP, RT-qPCR, and western blot assay.
resultsTET1, TET3, WDHD1, and MINPP1 are all expressed at high levels in tumor tissues of patients with LUAD. TET1/TET3 upregulated WDHD1 expression through demethylation and further mediated MINPP1 transcriptional activation. Administration of the glycolysis inhibitor 2-DG reversed the LUAD glycolytic program, and progression was inhibited by the knockdown of MINPP1. Restoration of MINPP1 also reversed glycolysis and proliferation suppressed by the knockdown of WDHD1. Finally, reactivation of WDHD1 promoted LUAD cell glycolysis and growth, curtailed by knockdown of TET1/TET3.
conclusionThe demethylases TET1/TET3 mediate the demethylation of the WDHD1 promoter to upregulate WDHD1 expression, thereby activating MINPP1 transcription to promote LUAD glycolysis and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.